input
correction
The results of a clinical trial confirming the effectiveness of IPX203, a new treatment for Parkinson’s disease, a central nervous system disease, have been published.
Parkinson’s disease is a central nervous system disease in which motor disorders such as muscle stiffness, body tremors, and slow movements occur as nerve cells producing dopamine, a neurotransmitter secreted in the brain region that controls movement, gradually disappear.
Health Day News reported on the 27th (local time) that the research team led by Professor Alberto Espai of the Department of Neurology and Rehabilitation Medicine at the University of Cincinnati, USA, confirmed the effectiveness of IPX203 in a nine-month clinical trial on 419 patients with Parkinson’s disease.
The research team said that even if IPX203 was administered only three times a day, the effect was better than that of levodopa, which requires five times a day, and the duration of the effect was 30 minutes longer.
The IPX203 capsule developed by Amneal, a US pharmaceutical company, is an improved version of levodopa, which is currently used as a treatment for Parkinson’s disease.
It is a mixture of levodopa granules that are immediately absorbed into the body and levodopa beads, which are slow-release tablets that are absorbed slowly.
If IPX203 is approved by the US Food and Drug Administration (FDA), the research team expects that IPX203 will be administered 5 times a day like the currently used levodopa.
Doing so will stabilize the drug concentration in the blood and the duration of the effect will be longer, the research team said.
The research team added that Parkinson’s disease patients would not find it cumbersome to administer the drug multiple times a day if the time for symptoms to be alleviated was longer.
Parkinson’s disease has been treated with levodopa for a long time.
Levodopa is converted into dopamine, a neurotransmitter that is deficient in people with Parkinson’s disease.
Levodopa is the same as insulin when it comes to diabetes.
Patients with Parkinson’s disease need five daily doses of levodopa to maintain a stable level of dopamine in the blood.
The side effects of IPX203 were urinary tract infection, back pain, and constipation, and most of the symptoms were mild to moderate.
These side effects appeared within the first 90 days of dosing.
The US FDA is currently reviewing the efficacy of IPX203.
The FDA expects to approve IPX203 in the fall or early winter of this year, the team expects.
Dr. Anna Holler, head of neurology at St. Elizabeth Medical Center, commented that if IPX203 is approved, Parkinson’s disease patients will have another opportunity to choose a treatment option.
The trial results were presented at the annual meeting of the American Academy of Neurology in Boston.
/yunhap news
2023-04-28 00:24:55
#Parkinsons #disease #drug #IPX203 #clinical #trial #proves #effectiveness
